Are You Interested In Investing In Zomedica Corp. (ZOM)? Check This Out First

0
4

As of Wednesday close, Zomedica Corp.’s (AMEX:ZOM) stock traded at $0.20. The average number of shares traded per day over the past five days has been 5,323,220 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.0179 fall in that time frame. In the last twenty days, the average volume was 6,909,160, while in the previous 50 days, it was 6,896,462.

Since last month, ZOM stock retreated -8.52%. Shares of the company fell to $0.1990 on 11/23/22, the lowest level in the past month. A 52-week high of $0.50 was reached on 02/17/22 after having rallying from a 52-week low of $0.17. Since the beginning of this year, ZOM’s stock price has dropped by -33.44% or -$0.1025, and marked a new high 4 times. However, the stock has declined by -59.20% since its 52-week high.


Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored


Valuation Metrics

The stock’s beta is 0.73. Besides these, the trailing price-to-sales (P/S) ratio of 16.41, the price-to-book (PB) ratio of 0.76.

Financial Health

In the three months ended December 30, Zomedica Corp.’s quick ratio stood at 17.50, while its current ratio was 17.80, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 73.20% percent. Based on annual data, ZOM earned $3.05 million in gross profit and brought in $4.13 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -6.80%. Return on equity (ROE) for the past 12 months was -6.50%.

According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ZOM’s revenue rose 99.58% to $4.25 million during the quarter, while net income inched up to $4.78 million. While analysts expected Zomedica Corp. to report $0 quarterly earnings, the actual figure was -$0.01 per share. During the quarter, the company generated -$5.84 million in EBITDA. The liabilities of Zomedica Corp. were 13.52 million at the end of its most recent quarter ended December 30, and its total debt was $1.71 million. The value of shareholders’ equity is $979.95 million.

Technical Picture

This quick technical analysis looks at Zomedica Corp.’s (ZOM) price momentum. With a historical volatility rate of 48.66%, the RSI 9-day stood at 32.93% on 23 November.

With respect to its five-day moving average, the current Zomedica Corp. price is down by -8.07% percent or -$0.0179. At present, ZOM shares trade -8.31% below its 20-day simple moving average and -7.27% percent below its 100-day simple moving average. However, the stock is currently trading approximately -11.34% below its SMA50 and -30.14% below its SMA200.

Stochastic coefficient K was 6.89% and Stochastic coefficient D was 6.16%, while ATR was 0.0118. Given the Stochastic reading of 9.82% for the 14-day period, the RSI (14) reading has been calculated as 38.73%. As of today, the MACD Oscillator reading stands at -0.0149, while the 14-day reading stands at -0.0185.

Analyst Ratings

Zomedica Corp. (ZOM) has been rated Buy by analysts. According to 0 brokerage firms, ZOM is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Zomedica Corp. stock as buy, with 1 recommending it as overweight.

LEAVE A REPLY

Please enter your comment!
Please enter your name here